DiaMedica Therapeutics, Inc.
DiaMedica-Logo
Navigate DiaMedica Therapeutics, Inc.
Home
About Us
Company Overview
Leadership Team
Board of Directors
Clinical Advisory Boards
Science
Our Science
Pipeline
Diseases We Target
Overview
IgA Nephropathy
African Americans - Hypertensive with CKD
Acute Ischemic Stroke
Investors & Media
Investors Home
Press Releases
Events & Presentations
Nasdaq Stock Information
Analyst Coverage
Financial Reports
Governance
Investor Resources
Careers
Contact
Home
News
News
All News
By Year:
2020
2019
2018
2017
2016
May 1, 2017
DiaMedica Announces Recently Granted Formulation Patent in U.S. for DM199
Apr 25, 2017
DiaMedica Announces Dr. Nancy Chang to its Strategic Advisory Board
Apr 18, 2017
DiaMedica Therapeutics Completes Private Placement With U.S. Based Family Office
Mar 20, 2017
DiaMedica Announces Issuance of European Composition of Matter Patent and Additional Worldwide Filings for DM199
Mar 13, 2017
DiaMedica Presents Updated Positive DM199 Phase Ib Trial Identifying A Superior Subcutaneous Delivery Profile
Dec 23, 2016
DiaMedica Announces Name Change to DiaMedica Therapeutics Inc.
Dec 20, 2016
DiaMedica Announces Positive Top-Line Results from DM199 Bridging Clinical Trial
Dec 7, 2016
DiaMedica Expands its Business Development Capabilities
Dec 1, 2016
DiaMedica Announces the Sale and Transfer of its DM-71 Product for Type 2 Diabetes
Nov 28, 2016
DiaMedica Inc. Announces Results of Annual General and Special Meeting of Shareholders
« Previous
1
2
3
4
5
6
7
8
Next »